Blonanserin

• Description :

  Blonanserin (AD-5423) is a potent and orally active 5-HT2A (Ki=0.812 nM) and dopamine D2 receptor (Ki =0.142 nM) antagonist. Blonanserin is usually acts as an atypical antipsychotic agent and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension[1].

• Product Name Alternative :

  AD-5423

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  5-HT Receptor; Adrenergic Receptor; Dopamine Receptor; Sigma Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/Blonanserin.html

• Purity :

  99.62

• Solubility :

  DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  FC1=CC=C(C2=C(CCCCCC3)C3=NC(N4CCN(CC)CC4)=C2)C=C1

• Molecular Formula :

  C23H30FN3

• Molecular Weight :

  367.50

• Precautions :

  H302

• References & Citations :

  [1]Blonanserin|[2]Saori Takeuchi, et al. Blonanserin ameliorates social deficit through dopamine-D 3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. Neurochem Int. 2019 Sep;128:127-134.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  5-HT2 Receptor; D1 Receptor; D2 Receptor; D3 Receptor; D4 Receptor; MUC2; α adrenergic receptor; α-1 microglobulin

• CAS Number :

  [132810-10-7]